Albemarle Reports Second Quarter 2012 Results

BATON ROUGE, La., July 17, 2012 /PRNewswire/ --

Second quarter 2012 highlights:

  • Quarterly net income of $111.3 million before special items, or $1.24 per share.
  • Eleventh consecutive quarter of year-over-year earnings per share growth, excluding specials.
  • EBITDA of $180.9 million and EBITDA margin of 26 percent for the quarter, before special items.
  • One-time pre-tax charge of $94.7 million related to exit of phosphorous flame retardants business.

 


Three Months Ended


Six Months Ended



June 30,


June 30,


In thousands, except per share amounts

2012


2011


2012


2011















Net sales

$

684,894


$

742,108


$

1,396,598


$

1,438,638















Segment income

$

174,927


$

180,180


$

349,190


$

351,780















Net income attributable to Albemarle Corporation

$

37,732


$

114,159


$

145,775


$

220,739















Diluted earnings per share

$

0.42


$

1.23


$

1.62


$

2.38















Special items per share

$

0.82


$


$

0.82


$















Diluted earnings per share excluding special items

$

1.24


$

1.23


$

2.44


$

2.38















 

Albemarle Corporation (NYSE: ALB) reported second quarter 2012 earnings of $37.7 million, or $0.42 per share, compared to second quarter 2011 earnings of $114.2 million, or $1.23 per share.  Second quarter 2012 results include after-tax charges amounting to $73.6 million, or $0.82 per share, ($94.7 million before tax) in connection with our previously announced plan to exit the phosphorous flame retardants business.  The Company reported net sales of $684.9 million in the second quarter of 2012 compared to net sales of $742.1 million in the second quarter of 2011.

(Logo:  http://photos.prnewswire.com/prnh/20111129/MM14279LOGO )

Earnings for the first half of 2012 were $145.8 million, or $1.62 per share, compared to $220.7 million, or $2.38 per share, for the first half of 2011.  Excluding after-tax charges amounting to $73.6 million, or $0.82 per share ($94.7 million before tax) for special items in the second quarter of 2012, earnings for the first half of 2012 were $219.4 million, or $2.44 per share.  Net sales for the first half of 2012 were $1.40 billion compared to $1.44 billion for the first half of 2011. 

"I am pleased to announce our second quarter results, which mark our 11th consecutive quarter of year over year earnings per share growth," said Luke Kissam, CEO.  "In spite of a challenging economic environment, each of our businesses delivered solid earnings and margins, and Fine Chemistry recorded its highest quarterly earnings ever.  While we currently are not seeing the increased market demand that we had expected in the second half of the year, our businesses remain fundamentally healthy and strategically well positioned. We remain focused on delivering value to our customers and solid financial results through these uncertain times."

Quarterly Segment Results

Catalysts generated net sales of $229.1 million in the second quarter of 2012, a 14 percent decrease from net sales in the second quarter of 2011, due mainly to a mix shift from HPC to FCC as well as unfavorable foreign currency impacts, partially offset by higher overall volumes.  Catalysts segment income was $67.1 million in the second quarter of 2012, up 2 percent over second quarter 2011 results of $65.6 million due primarily to lower input costs, offset mainly by lower equity income versus the second quarter of 2011. 

Polymer Solutions delivered net sales of $247.0 million in the second quarter of 2012, a 15 percent decrease over net sales in the second quarter of 2011, due mainly to lower volumes and unfavorable foreign currency impacts, partly offset by favorable pricing.  Segment income for Polymer Solutions was $64.1 million in the second quarter of 2012, a 17 percent decline from $77.2 million in the second quarter of 2011, due primarily to lower volumes, partly offset by favorable pricing, lower input costs and lower charges attributable to the noncontrolling interest in our Jordanian joint venture.

Fine Chemistry net sales in the second quarter of 2012 were $208.7 million, a 13 percent increase over net sales in the second quarter of 2011, due mainly to favorable volumes and pricing, partly offset by unfavorable foreign currency impacts.  Segment income for Fine Chemistry was $43.8 million for the second quarter of 2012, up 17 percent over second quarter 2011 results of $37.4 million, due primarily to favorable volume and pricing and lower charges attributable to the noncontrolling interest in our Jordanian joint venture, partly offset by higher input costs.

Corporate and Other

Corporate and other expense was $18.6 million for the second quarter of 2012.  The decrease over the comparable period in 2011 was due primarily to lower personnel-related costs including performance-based incentive compensation. 

Interest and financing expenses were $8.5 million for the second quarter of 2012 compared to $9.3 million for the second quarter of 2011, with this decrease due primarily to increases in interest capitalized on higher average construction project balances outstanding year over year.

Our second quarter 2012 effective income tax rate was 34.1 percent versus 21.7 percent in the second quarter of 2011.  Excluding special items, our second quarter 2012 effective income tax rate was 26.0 percent.  Our effective tax rate continues to be influenced by the level and geographic mix of income, and benefits from a favorable mix of income in lower tax jurisdictions. 

Cash Flow

Our cash flow from operations was approximately $185 million for the six months ended June 30, 2012, and we had $461.8 million in cash and cash equivalents at June 30, 2012.  In the first half of 2012, cash on hand and cash provided by operations funded capital expenditures for plant, machinery and equipment of approximately $126.6 million (which includes approximately $44.0 million in capital expenditures associated with our Jordanian joint venture), long-term debt repayments of $9.4 million, dividends to shareholders of $33.4 million and repurchases of $13.7 million of our common stock. 

Outlook

Uncertainty persists regarding the condition of the global economy.  During the second quarter, we saw a steady deterioration of certain of the indicators that we use to gauge the health of and demand in the markets that our businesses serve, particularly within electronics. In addition, Catalysts will face challenging year over year comparisons.

Earnings Call

The Company's performance for the second quarter ended June 30, 2012 will be discussed on a conference call at 9:00 AM Eastern Daylight time on July 18, 2012.  The call can be accessed by dialing 800-638-5439 (International Dial In # 617-614-3945), and entering conference ID 95471699.  The Company's earnings presentation and supporting material can be accessed through Albemarle's website under Investors at www.albemarle.com.

About Albemarle

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services.  Albemarle is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts and Fine Chemistry, with Corporate Responsibility Magazine naming Albemarle among its prestigious "100 Best Corporate Citizens" list for 2011.  Albemarle employs more than 4,000 people worldwide and serves customers in approximately 100 countries.  Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, Regulation G reconciliations, SEC filings and other information regarding the Company, its businesses and markets served. 

Forward-Looking Statements

Some of the information presented in this press release, including, without limitation, statements with respect to product development, improvements in productivity, market trends, price and mix changes, expected growth, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  There can be no assurance that actual results will not differ materially.  Factors that could cause actual results to differ from expectations include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; changes in the cost of raw materials and energy and in our inability to pass through increases; acquisitions and divestitures, and changes in performance of acquired companies; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of claims or litigation; the occurrence of natural disasters; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest, including terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings; changes in monetary policies or inflation or interest rates, which may impact our ability to raise capital or increase our cost of funds, the performance of our pension fund investments and our pension expense and funding obligations; volatility and substantial uncertainties in the debt and equity markets; technology or intellectual property infringement and other risks; decisions we may make in the future; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K and our 2012 Quarterly Reports on Form 10-Q. 

 

Albemarle Corporation and Subsidiaries
Consolidated Statements of Income
(In Thousands Except Per Share Amounts) (Unaudited)










Three Months Ended

Six Months Ended



June 30,

June 30,



2012


2011



2012


2011


Net sales

$

684,894


$

742,108



$

1,396,598


$

1,438,638


Cost of goods sold


442,209



490,159




906,026



953,673


Gross profit


242,685



251,949




490,572



484,965


Selling, general and administrative expenses (a)


74,624



82,907




155,316



155,946


Research and development expenses


20,911



19,947




39,960



37,562


Restructuring and other charges (b)


94,703






94,703




Operating profit


52,447



149,095




200,593



291,457


Interest and financing expenses


(8,486)



(9,274)




(17,220)



(18,866)


Other expenses, net


(688)



(760)




(806)



(422)


Income before income taxes and equity in net














   income of unconsolidated investments


43,273



139,061




182,567



272,169


Income tax expense


14,747



30,154




50,213



62,326


Income before equity in net income of














   unconsolidated investments


28,526



108,907




132,354



209,843


Equity in net income of unconsolidated














   investments (net of tax)


12,712



14,787




21,298



27,618


Net income


41,238



123,694




153,652



237,461


Net income attributable to noncontrolling interests


(3,506)



(9,535)




(7,877)



(16,722)


Net income attributable to Albemarle Corporation

$

37,732


$

114,159



$

145,775


$

220,739
















Basic earnings per share

$

0.42


$

1.24



$

1.63


$

2.41


Diluted earnings per share

$

0.42


$

1.23



$

1.62


$

2.38


Weighted-average common shares outstanding –
   
basic















89,414



91,713




89,206



91,673


Weighted-average common shares outstanding – 
   diluted















90,051



92,795




89,999



92,656
















See accompanying notes to the condensed consolidated financial information.



 

 

Albemarle Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In Thousands) (Unaudited)








June 30,



December 31,



2012



2011


ASSETS








Cash and cash equivalents

$

461,751



$

469,416


Other current assets


989,924




886,204










Total current assets


1,451,675




1,355,620










Property, plant and equipment


2,725,084




2,619,428


Less accumulated depreciation

   and amortization


1,548,114




1,489,948


Net property, plant and equipment


1,176,970




1,129,480










Other assets and intangibles


674,062




718,724


Total assets

$

3,302,707



$

3,203,824










LIABILITIES AND EQUITY








Current portion of long-term debt

$

12,572



$

14,416


Other current liabilities


400,731




386,762










Total current liabilities


413,303




401,178










Long-term debt


742,252




749,257


Other noncurrent liabilities


283,007




296,659


Deferred income taxes


70,501




77,903


Albemarle Corporation shareholders' equity


1,705,690




1,591,277


Noncontrolling interests


87,954




87,550


Total liabilities & equity

$

3,302,707



$

3,203,824










See accompanying notes to the condensed consolidated financial information.

 

 

Albemarle Corporation and Subsidiaries
Selected Consolidated Cash Flow Data
(In Thousands) (Unaudited)





Six Months Ended



June 30,



2012


2011









Cash and cash equivalents at beginning of year

$

469,416


$

529,650


Cash and cash equivalents at end of period

$

461,751


$

490,715









Sources of cash and cash equivalents:














  Net income


153,652



237,461









  Proceeds from borrowings


614



14,558









  Proceeds from exercise of stock options


13,430



1,082









Uses of cash and cash equivalents:














  Capital expenditures


(126,623)



(67,627)









  Repurchases of common stock


(13,695)











  Repayments of long-term debt


(9,383)



(105,206)









  Dividends paid to shareholders


(33,399)



(27,960)









  Pension and postretirement contributions


(4,612)



(55,751)









  Investments in equity and other corporate investments




(10,868)









  Long-term advances to joint venture


(10,000)











Non-cash items:














  Depreciation and amortization


49,449



47,310









  Restructuring and other charges (b)


94,703











  Equity in net income of unconsolidated investments


(21,298)



(27,618)









See accompanying notes to the condensed consolidated financial information.

 

 

Albemarle Corporation and Subsidiaries
Consolidated Summary of Segment Results
(In Thousands) (Unaudited)








Three Months Ended



Six Months Ended



June 30,



June 30,



2012



2011



2012



2011


Net sales:
















Polymer Solutions

$

247,016



$

290,450



$

475,147



$

548,673


Catalysts


229,144




266,851




522,666




527,808


Fine Chemistry


208,734




184,807




398,785




362,157


Total net sales

$

684,894



$

742,108



$

1,396,598



$

1,438,638


















Segment operating profit:
















Polymer Solutions

$

61,811



$

78,850



$

114,523



$

148,681


Catalysts


56,304




53,438




131,719




115,569


Fine Chemistry


47,583




42,635




89,507




76,594


Total segment operating profit


165,698




174,923




335,749




340,844


















Equity in net income of unconsolidated investments:
















Polymer Solutions


1,913




2,650




3,758




5,139


Catalysts


10,799




12,165




17,540




22,626


Fine Chemistry












Corporate & other





(28)







(147)


Total equity in net income of unconsolidated investments


12,712




14,787




21,298




27,618


















Net (income) loss attributable to noncontrolling interests:
















Polymer Solutions


349




(4,333)




(653)




(7,179)


Catalysts












Fine Chemistry


(3,832)




(5,225)




(7,204)




(9,650)


Corporate & other


(23)




23




(20)




107


Total net income attributable to noncontrolling interests


(3,506)




(9,535)




(7,877)




(16,722)


















Segment income:
















Polymer Solutions


64,073




77,167




117,628




146,641


Catalysts


67,103




65,603




149,259




138,195


Fine Chemistry


43,751




37,410




82,303




66,944


Total segment income


174,927




180,180




349,190




351,780


Corporate & other


(18,571)




(25,833)




(40,473)




(49,427)


Restructuring and other charges (b)


(94,703)







(94,703)





Interest and financing expenses


(8,486)




(9,274)




(17,220)




(18,866)


Other expenses, net


(688)




(760)




(806)




(422)


Income tax expense


(14,747)




(30,154)




(50,213)




(62,326)


Net income attributable to Albemarle Corporation

$

37,732



$

114,159



$

145,775



$

220,739


















See accompanying notes to the condensed consolidated financial information.

 

Notes to the Condensed Consolidated Financial Information

(a)  The six month period ended June 30, 2012 includes a gain of $8.1 million ($5.1 million after tax, or 6 cents per share) resulting from proceeds received in connection with the settlement of litigation (net of related legal fees).  The six month period ended June 30, 2012 also includes an $8 million charitable contribution ($5.1 million after tax, or 6 cents per share) to the Albemarle Foundation. 

(b)  The three and six month periods ended June 30, 2012 include charges amounting to $94.7 million ($73.6 million after income taxes, or $0.82 per share) in connection with our previously announced plan to exit the phosphorous flame retardants business 

Additional Information

It should be noted that earnings, earnings per share and effective income tax rates which exclude special items, as well as presentations of segment operating profit, segment income, EBITDA, EBITDA excluding special items, EBITDA margin and EBITDA margin excluding special items are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP.  These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance.

A description of other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Investors section of our website at www.albemarle.com, under "Non-GAAP Reconciliations" under "Financials."  Also, see attached for a supplemental reconciliation of our segment operating profit and segment income amounts to GAAP Operating profit and GAAP Net income attributable to Albemarle Corporation, respectively, as well as for a supplemental reconciliation of our GAAP Net income attributable to Albemarle Corporation to EBITDA and EBITDA excluding special items.


ALBEMARLE CORPORATION AND SUBSIDIARIES
Non-GAAP Reconciliation
(In Thousands)
(Unaudited)

Our segment information includes measures we refer to as "segment operating profit," "segment income," "EBITDA" and "EBITDA excluding special items," which are financial measures that are not required by, or presented in accordance with, GAAP.  The Company has reported segment operating profit, segment income, EBITDA and EBITDA excluding special items because management believes that these financial measures provide transparency to investors and enable period-to-period comparability of financial performance.  Segment operating profit, segment income, EBITDA and EBITDA excluding special items should not be considered as alternatives to operating profit or net income attributable to Albemarle Corporation, as determined in accordance with GAAP.

See below for a reconciliation of segment operating profit and segment income, the non-GAAP financial measures, to Operating profit and Net income attributable to Albemarle Corporation, respectively, the most directly comparable financial measures calculated and reported in accordance with GAAP.

 


Three Months Ended


Six Months Ended



June 30,


June 30,



2012


2011


2012


2011















Total segment operating profit

$

165,698


$

174,923


$

335,749


$

340,844


Corporate & other *


(18,548)



(25,828)



(40,453)



(49,387)


Restructuring and other charges


(94,703)





(94,703)




GAAP Operating profit

$

52,447


$

149,095


$

200,593


$

291,457















Total segment income

$

174,927


$

180,180


$

349,190


$

351,780


Corporate & other


(18,571)



(25,833)



(40,473)



(49,427)


Restructuring and other charges


(94,703)





(94,703)




Interest and financing expenses


(8,486)



(9,274)



(17,220)



(18,866)


Other expenses, net


(688)



(760)



(806)



(422)


Income tax expense


(14,747)



(30,154)



(50,213)



(62,326)


GAAP Net income attributable to Albemarle Corporation

$

37,732


$

114,159


$

145,775


$

220,739















* Excludes corporate equity income and noncontrolling interest adjustments of $(23) and $(5) for the three-month periods ended June 30, 2012 and 2011, respectively, and $(20) and $(40) for the six-month periods ended June 30, 2012 and 2011, respectively.

 

See below for a reconciliation of EBITDA and EBITDA excluding special items, the non-GAAP financial measures, from net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP.  EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, depreciation and amortization.  EBITDA excluding special items is defined as EBITDA before the special items as listed below.

 


Three Months Ended


Six Months Ended



June 30,


June 30,



2012


2011


2012


2011















Net income attributable to Albemarle Corporation

$

37,732


$

114,159


$

145,775


$

220,739















Add:













Interest and financing expenses


8,486



9,274



17,220



18,866


Income tax expense


14,747



30,154



50,213



62,326


Depreciation and amortization


25,214



24,306



49,449



47,310


EBITDA


86,179



177,893



262,657



349,241


Restructuring and other charges


94,703





94,703




EBITDA excluding special items

$

180,882


$

177,893


$

357,360


$

349,241















Net sales

$

684,894


$

742,108


$

1,396,598


$

1,438,638















EBITDA Margin


12.6

%


24.0

%


18.8

%


24.3

%














EBITDA Margin excluding special items


26.4

%


24.0

%


25.6

%


24.3

%

 

SOURCE Albemarle Corporation



RELATED LINKS
http://www.albemarle.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.